Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C virus infection

INTERVENTION: Warfarin (anticoagulation) for a duration of two years at a dose to maintain the international normalised ratio (INR) at 2 ‐ 3. The warfarin will be taken orally on a daily basis. The control group will receive standard post‐transplant care only. The follow‐up duration of the trial is the duration of the intervention i.e., two years, after which patients will be followed up as per routine clinical care in their respective liver transplant clinics. CONDITION: Liver fibrosis, hepatitis C ; Infections and Infestations ; Hepatitis PRIMARY OUTCOME: Stage of liver fibrosis at end of treatment period (two years) SECONDARY OUTCOME: 1. Number of activated hepatic stellate cells per high power field on liver biopsy; 2. Non‐invasive measures of liver fibrosis INCLUSION CRITERIA: 1. Hepatitis C virus (HCV) infection 2. Aged over 17, either sex 3. Liver transplant within previous 4 months 4. Informed consent